As global markets continue to experience robust growth, with U.S. small-cap indices like the Russell 2000 reaching record highs, investor sentiment remains buoyed by domestic policy decisions and geopolitical developments. In this environment of heightened market activity and economic indicators showing mixed signals, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic landscapes.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Material Group |
20.45% |
24.01% |
★★★★★★ |
|
Seojin SystemLtd |
35.41% |
39.86% |
★★★★★★ |
|
Yggdrazil Group |
24.66% |
85.53% |
★★★★★★ |
|
eWeLLLtd |
27.24% |
28.74% |
★★★★★★ |
|
Waystream Holding |
22.09% |
113.25% |
★★★★★★ |
|
Mental Health TechnologiesLtd |
24.68% |
97.53% |
★★★★★★ |
|
Medley |
25.57% |
31.67% |
★★★★★★ |
|
Fine M-TecLTD |
36.23% |
131.08% |
★★★★★★ |
|
Elliptic Laboratories |
70.09% |
111.37% |
★★★★★★ |
|
JNTC |
29.48% |
104.37% |
★★★★★★ |
Click here to see the full list of 1286 stocks from our High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★★
Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across several regions, including the United States, Japan, Europe, the Middle East, Africa, and China, with a market cap of €35.60 billion.
Operations: The company primarily generates revenue from its biotechnology segment, amounting to $1.91 billion. Its focus is on developing therapies for autoimmune diseases across multiple regions, contributing to its substantial market presence.
Armed with a robust pipeline, argenx is making significant strides in the biotech sector, particularly with its innovative treatments for autoimmune diseases. Recently, the company reported a notable revenue increase to $588.88 million in Q3 2024 from $339.84 million in the previous year, underscoring a growth trajectory with an impressive 55.35% forecasted annual earnings growth rate. Furthermore, argenx’s commitment to R&D is evident as it continues to invest heavily; this dedication supports their ongoing Phase 2/3 ALKIVIA study which has shown promising results and met its primary endpoint at Week 24. These developments not only highlight argenx’s potential in delivering next-generation therapies but also position it well within the high-growth tech sphere of biotechnology, driven by both scientific innovation and strategic market expansions.
